Corcept Therapeutics Incorporated (CORT)
Summary
Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
Corcept Therapeutics is upgraded to Buy after a patent loss and FDA setback, with focus shifting to relacorilant in oncology. Despite Korlym's imminent generic erosion, CORT's $524M liquidity and cost controls provide a six-quarter runway to finance relacorilant's commercialization. Exceptional Phase 3 ROSELLA data in platinum-resistant ovarian cancer position relacorilant for "standard-of-care" status and potentially $3.38B in peak sales.
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in platinum-resistant ovarian cancer.
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum.
Corcept Therapeutics Incorporated (CORT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Corcept Therapeutics Incorporated ever had a stock split?
Corcept Therapeutics Incorporated Profile
| Biotechnology Industry | Healthcare Sector | Joseph K. Belanoff CEO | NASDAQ (CM) Exchange | 218352102 CUSIP |
| US Country | 500 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Corcept Therapeutics Incorporated is a pioneer in the pharmaceutical industry with a focus on the discovery and development of medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. Operating within the United States, the company has made significant strides in addressing complex health conditions by offering effective solutions. Founded in 1998 and headquartered in Menlo Park, California, Corcept has established itself as a leader in targeting illnesses related to hormonal imbalances and their consequences, thereby improving the quality of life for patients with unique and challenging medical conditions.
Products and Services
- Korlym tablets:
Korlym is an essential medication designed for the treatment of hyperglycemia secondary to hypercortisolism in adult patients diagnosed with endogenous Cushing's syndrome. This medication is particularly beneficial for those who have type 2 diabetes mellitus or glucose intolerance, and have either failed surgery or are not candidates for surgery. Through its targeted action, Korlym provides a critical healthcare solution to a niche patient demographic.
- Relacorilant:
Currently in phase III clinical trial, relacorilant is being developed as an advanced treatment solution for Cushing's syndrome. Beyond this application, relacorilant is also under investigation for its potential in treating adrenal cancer and cortisol excess (phase 1b clinical trial), prostate cancer (phase II clinical trial), and in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian tumors (phase III clinical trial).
- Dazucorilant:
In its phase II clinical trial stage, dazucorilant is being explored as a possible therapeutic option for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disorder. This indication underscores Corcept's commitment to addressing complex neurologic conditions.
- Miricorilant:
Miricorilant is undergoing a phase IIb trial to assess its efficacy in treating nonalcoholic steatohepatitis (NASH), a liver disease. This development process aligns with Corcept's mission to provide treatments for metabolic disorders.
- Treatment for Antipsychotic Induced Weight Gain:
This investigative treatment, currently in phase I trial, addresses a significant side effect associated with antipsychotic medications: weight gain. With this initiative, Corcept aims to offer a solution to improve the overall management and quality of life for patients on antipsychotic therapy.
